Q-omics provides the consensus-scored MIR23B profile across patient tissues and cancer cell-line models. MIR23B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR23B is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, MIR23B RNA expression shows 12,085 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, LUSC, and CCRCC as cancer lineages where MIR23B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR23B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR23B survival associations across molecular data types. MIR23B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR23B RNA expression–survival associations across cancer types. High MIR23B expression shows unfavorable associations in UVM, READ and LGG, but favorable associations in HNSC, UCS and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR23B RNA expression.
This table summarizes MIR23B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR23B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR23B shows lower tumor expression in LUSC, LUAD, UCEC, BRCA, HNSC and KIRC. The LUSC box plot shows higher MIR23B RNA expression in normal versus tumor tissue (log2 FC = −1.824, t-test p < 0.001).
This table shows molecular features associated with MIR23B in patient tissues and cancer cell lines. In patient samples, MIR23B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
